{"entity":{"id":"james-larkin","kind":"person","name":"James Larkin","aka":[],"tldr":"Melanoma and kidney cancer trialist who co-led CheckMate 067, the trial with 10-year immunotherapy survival data.","summary":"James Larkin is a consultant medical oncologist at The Royal Marsden and Professor at The Institute of Cancer Research. His specialisms are melanoma, renal cell carcinoma and immunotherapy combinations. He was a lead investigator of CheckMate 067, the trial of nivolumab plus ipilimumab in advanced melanoma, and of CheckMate 9ER in renal cell carcinoma, work that shaped first-line immunotherapy in both diseases. His New England Journal of Medicine paper reported the long-term results of combined nivolumab and ipilimumab in advanced melanoma from CheckMate 067. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Larkin%20J%5BAuthor%5D%20melanoma%20nivolumab%20ipilimumab"}],"tags":[],"related":[],"cancers":["melanoma","rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab","ipilimumab"],"companies":[],"institutions":["royal-marsden","icr-london"],"pathways":[],"terms":[],"trials":["checkmate-067","checkmate-9er"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Consultant Medical Oncologist, Royal Marsden; Professor, ICR","institutionId":"royal-marsden","specialisms":["Melanoma","Renal cell carcinoma","Immunotherapy combinations"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Larkin%20J%5BAuthor%5D%20melanoma%20nivolumab%20ipilimumab"}],"papers":[{"title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma (CheckMate 067)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1910836"},{"title":"CheckMate 067 at ten years: half of melanoma patients treated with nivolumab plus ipilimumab were alive a decade later","journal":"New England Journal of Medicine","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CheckMate%20067%2010-year%20nivolumab%20ipilimumab%20melanoma%20Wolchok%20NEJM%202025"},{"title":"CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma","journal":"New England Journal of Medicine","year":2025,"url":"https://doi.org/10.1056/NEJMoa2407417","doi":"10.1056/NEJMoa2407417"}],"orcid":"0000-0001-5569-9523"},"route":"/people/james-larkin/","neighbours":{"cancer":[{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"institution":[{"id":"icr-london","kind":"institution","name":"The Institute of Cancer Research","route":"/institutions/icr-london/"},{"id":"royal-marsden","kind":"institution","name":"The Royal Marsden","route":"/institutions/royal-marsden/"}],"trial":[{"id":"checkmate-067","kind":"trial","name":"CheckMate 067","route":"/trials/checkmate-067/"},{"id":"checkmate-238","kind":"trial","name":"CheckMate 238","route":"/trials/checkmate-238/"},{"id":"checkmate-9er","kind":"trial","name":"CheckMate 9ER","route":"/trials/checkmate-9er/"},{"id":"cobrim","kind":"trial","name":"coBRIM","route":"/trials/cobrim/"}],"paper":[{"id":"paper-checkmate-067-10-year-nejm-2025","kind":"paper","name":"CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma","route":"/key-papers/paper-checkmate-067-10-year-nejm-2025/"}]}}